SURVIVAL OF PATIENTS WITH ADVANCED HER2+ BREAST CANCER. ANALYSIS OF A CANCER CENTER DATABASE
Características clínicas y pronóstico de pacientes con cáncer de mama HER2 positivo avanzado, en la era antes y después de terapias anti HER2
| dc.contributor | en-US | |
| dc.contributor | es-ES | |
| dc.creator | Sánchez, César; Profesor asistente Departamento Hematología-OncoloPontifica Universidad Católica de Chile | |
| dc.creator | Domínguez, Francisco; Facultad de Medicina. Pontifica Universidad Católica de Chile | |
| dc.creator | Galindo, Héctor; Facultad de Medicina. Pontifica Universidad Católica de Chile | |
| dc.creator | Camus, Mauricio; Facultad de Medicina. Pontifica Universidad Católica de Chile | |
| dc.creator | Oddo, David; Facultad de Medicina. Pontifica Universidad Católica de Chile | |
| dc.creator | Villarroel, Alejandra; Facultad de Medicina. Pontifica Universidad Católica de Chile | |
| dc.creator | Razmilic, Dravna; Facultad de Medicina. Pontifica Universidad Católica de Chile | |
| dc.creator | Navarro, María Elena; Facultad de Medicina. Pontifica Universidad Católica de Chile | |
| dc.creator | Perez-Sepúlveda, Alejandra; Facultad de Medicina. Pontifica Universidad Católica de Chile | |
| dc.creator | Medina, Lidia; Centro de Cancer. Red de Salud UC Christus. | |
| dc.creator | López, Valeska; Centro de Cancer. Red de Salud UC Christus. | |
| dc.creator | Acevedo, Francisco; Facultad de Medicina. Pontifica Universidad Católica de Chile | |
| dc.date | 2018-10-01 | |
| dc.date.accessioned | 2019-11-11T18:27:37Z | |
| dc.date.available | 2019-11-11T18:27:37Z | |
| dc.identifier | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6803 | |
| dc.identifier.uri | https://revistaschilenas.uchile.cl/handle/2250/111212 | |
| dc.description | Background: HER2 breast cancer (BC) subtype overexpresses the Human Epidermal growth factor Receptor type-2 (HER2) and is characterized by its aggressiveness and its high sensitivity to monoclonal antibody-based HER2-targeted therapies. Aim: To assess the prognosis and evaluate the impact of novel anti-HER2 therapies on advanced HER2+ BC patients treated at our institution over the last decades. Material and methods: Analysis of the patient database at a cancer center of a university hospital. Information about the subtype of cancer was obtained in 2149 of 2724 patients in the database. Eighteen percent of the latter were HER2+. We analyzed data of 83 of these patients with advanced disease. Results: Median overall survival (OS) was 24 months. For patients treated between 1997-2006 median OS was 17 months and for those treated in the period 2007-2017 median OS was 32 months (p=0.09). Conclusions: A non-significant trend towards better survival in the last decade was observed. HER2+ BC overall survival has improved in our center. This can be probably attributed to the use of novel more effective anti-HER2 therapies. | en-US |
| dc.description | Background: HER2 breast cancer (BC) subtype overexpresses the Human Epidermal growth factor Receptor type-2 (HER2) and is characterized by its aggressiveness and its high sensitivity to monoclonal antibody-based HER2-targeted therapies. Aim: To assess the prognosis and evaluate the impact of novel anti-HER2 therapies on advanced HER2+ BC patients treated at our institution over the last decades. Material and methods: Analysis of the patient database at a cancer center of a university hospital. Information about the subtype of cancer was obtained in 2149 of 2724 patients in the database. Eighteen percent of the latter were HER2+. We analyzed data of 83 of these patients with advanced disease. Results: Median overall survival (OS) was 24 months. For patients treated between 1997-2006 median OS was 17 months and for those treated in the period 2007-2017 median OS was 32 months (p=0.09). Conclusions: A non-significant trend towards better survival in the last decade was observed. HER2+ BC overall survival has improved in our center. This can be probably attributed to the use of novel more effective anti-HER2 therapies. | es-ES |
| dc.format | application/pdf | |
| dc.language | spa | |
| dc.publisher | Revista Médica de Chile | es-ES |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6803/4385 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35215 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35216 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35219 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35220 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35221 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35222 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35223 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35224 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35225 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35226 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35227 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35228 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35312 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35377 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35378 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35716 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/35747 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/36632 | |
| dc.relation | http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6803/36719 | |
| dc.source | Revista Médica de Chile; Vol. 146, núm. 10 (2018): OCTUBRE 2018 | es-ES |
| dc.source | 0034-9887 | |
| dc.subject | Breast Neoplasms; Survival; Trastuzumab | en-US |
| dc.subject | Breast Neoplasms; Survival; Trastuzumab | es-ES |
| dc.title | SURVIVAL OF PATIENTS WITH ADVANCED HER2+ BREAST CANCER. ANALYSIS OF A CANCER CENTER DATABASE | en-US |
| dc.title | Características clínicas y pronóstico de pacientes con cáncer de mama HER2 positivo avanzado, en la era antes y después de terapias anti HER2 | es-ES |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
| dc.type | es-ES |